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1. Introduction 
The characteristic pathophysiology in rheumatoid arthritis (RA) is the destruction of bone 
and cartilage due to persistent synovitis of unknown etiology. Pro-inflammatory cytokines, 
including tumor necrosis factor alpha (TNFǂ), interleukin-1 (IL-1), and interleukin-6 (IL-6), 
are overproduced in inflamed synovial membranes, and are critically involved in the spread 
and persistence of the inflammation. IL-6, which was identified as a B-cell stimulatory factor 
in 1986, is a multifunctional cytokine (Hirano, 2010), and a key mediator in the pathological 
processes of RA, especially in the activation of immune cells and osteoclasts (Cronstein, 
2007). For RA drug therapy, therefore, inhibition of IL-6 signaling is suitable for shutting 
down both inflammation and bone destruction. Tocilizumab (TCZ) is a humanized 
monoclonal antibody (human IgG1 κ subclass) against IL-6 receptor (IL-6R). The data from 
the recent clinical studies on TCZ suggests that TCZ has several advantages over other anti-
rheumatic drugs (Bergman et al., 2010).  
2. Pharmacological properties 
2.1 Pharmacodynamics 
Human IL-6 binds to human IL-6 R with a dissociation constant (Kd) of 5.5 nM, and this low 
affinity complex subsequently recruits a gp130 molecule to form a high-affinity complex (IL-
6/IL-6R/gp130 ternary complex) with a Kd of 50 pM (Hibi et al, 1990). TCZ binds 
selectively and competitively to both soluble IL-6R (sIL-6R) and membrane bound IL-6R 
(mIL-6R) with a Kd of 0.71 nM and 2.54 nM, respectively (Japan Pharmacists Education 
Center, 2008; Mihara et al., 2005). TCZ suppressed the binding of IL-6 (10 ng/mL) to sIL-6R 
in a dose dependent manner at of a concentration between 0.002 and 4 µg/mL and 
completely inhibited at concentrations of > 4 µg/mL. Moreover, TCZ was able to dissociate 
IL-6/sIL-6R preformed complex which was made by mixing IL-6 (200 ng/mL) and sIL-6R 
(40 ng/mL). The percentage binding of IL-6 to sIL-6R fell in a TCZ concentration-dependent 
manner, and was less than 10% of the binding seen in the presence of TCZ at concentrations 
of > 1 µg/mL. On the other hand, the binding of TCZ to sIL-6R rose in a concentration-
dependent manner and reached a plateau at 0.1 µg/mL (Mihara et al., 2005). In vitro, 100 
µg/mL of TCZ completely inhibited cell growth of IL-6 dependent KT-3 cells in the presence 
of up to 0.32 ng/mL IL-6. Cell growth inhibition by TCZ was dose-dependently decreased 
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by IL-6 at concentrations of > 0.32 ng/mL, and no inhibition of cell growth by TCZ was 
observed in the presence of 1 µg/mL IL-6 (Australian Government, 2011). In vivo, serum 
levels of IL-6 and sIL-6R markedly increased after TCZ treatment in patients with RA. While 
free TCZ concentration remains 1 µg/mL or more, serum C-reactive protein (CRP) is 
normalized, indicating that sIL-6R is saturated with TCZ and IL-6 signaling is completely 
inhibited (Nishimoto et al., 2008).  
2.2 Pharmacokinetic properties 
PK data were based on a population PK analysis of 1793 patients with RA who received a 1 
hour infusion of TCZ 8mg/kg every 4 weeks for 24 weeks (Frey et al., 2010). The t 1/2 of TCZ 
was concentration-dependent. The effective t 1/2 decreased with decreasing concentrations 
of TCZ within a dosing interval from 14 days to 8 days. After administration of TCZ, the 
predicted steady-state the mean area under the concentration-time curve (AUC), maximum 
concentration (Cmax), the steady-state volume of distribution, and the trough concentration 
(Cmin) values were 35.0 mg·h/mL, 183 µg/mL, 6.4 L, and 9.7 µg/mL, respectively. The Cmin 
value is 91 fold higher that the Kd of TCZ for the binding at the sIL-6R (Kd is 0.71 nM = 0.10 
µg/ml). Therefore, IL-6R was completely occupied even at the end of each 8 mg/kg dosing 
interval in most of the patients. Age, gender and ethnicity did not affect the PK of TCZ. 
TCZ is not excreted via the renal or biliary route. Instead, TCZ is predominantly eliminated 
via catabolism including degradation in plasma and distribution to tissues. TCZ undergoes 
biphasic elimination from the circulation. Total clearance is concentration dependent and 
includes linear at higher TCZ concentrations and non-linear clearance at low TCZ 
concentration. No formal studies on the effect of renal or hepatic impairment on the PK of 
TCZ have been conducted. Mild renal impairment (creatinine clearance based on Cockcroft-
Gault < 80 ml/min and ≥ 50 ml/min) did not affect the PK of TCZ.  
Nor is the clearance of TCZ affected by concomitant use of methotrexate (MTX), 
nonsteroidal anti-inflammatory drugs (NSAIDs), or corticosteroids. TCZ may normalize the 
expression of hepatic cytochrome P450 (CYP) isozymes which are suppressed by IL-6 
(Oldfield et al., 2009). Therefore, administration or discontinuation of TCZ may affect the 
serum concentrations of drugs metabolized via CYP3A4, CYP1A2, CYP2C9 or CYP2C19 
(e.g., omeprazole, dextromethorphan, atorvastatin, simvastatin, calcium channel blockers, 
cyclosporine, and warfarin).  
3. Therapeutic efficacy 
3.1 Clinical studies 
In a 12-week, multicenter, randomized, double-blind, placebo-controlled phase I/II study, 
164 Japanese patients with refractory RA were randomly administered either placebo, or 4 
mg/kg or 8 mg/kg TCZ (Nishimoto et al., 2004). A dose-dependent reduction in the 
American College of Rheumatology (ACR) 20 response was observed. At 3 months, 78% of 
patients in the 8 mg/kg group, 57% in the 4 mg/kg group, and 11% in the placebo group 
achieved an ACR20 response. This study was extended to evaluate the long-term efficacy 
and safety of TCZ 8 mg/kg monotherapy for five years and designated STREAM (long-term 
Safety and efficacy of Tocilizumab, an anti-interleukin-6 REceptor monoclonal Antibody, in 
Monotherapy, in patients with rheumatoid arthritis) (Nishimoto et al., 2009a). A total 143 
patients were enrolled, and 94 patients completed 5 years. At 5 years, 84.0%, 69.1%, and 
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43.6% of the patients achieved ACR20, ACR50, and ACR70 responses, respectively. 
Remission (the 28-joint disease activity score using erythrocyte sedimentation rate 
(DAS28ESR) <2.6) was achieved in 55.3% of the patients. 
The CHARISMA (the Chugai Humanized Anti-human Recombinant Interleukin-Six 
Monoclonal Antibody) study was a 16-week, multicenter, randomized, double-blind, 
placebo-controlled phase II trial in 359 European patients in whom the response to MTX was 
inadequate (Maini et al., 2006). ACR20 response was achieved by 61% and 63% of patients 
receiving 4 mg/kg and 8 mg/kg of TCZ as monotherapy, respectively. 
There are seven phase III studies (Table 1). SAMURAI  (Study of Active controlled 
Monotherapy Used for Rheumatoid Arthritis, an Interleukin-6 inhibitor) was a randomized, 
52-week, multicenter, x-ray reader-blinded, controlled phase III trial to evaluate the ability 
of TCZ monotherapy to inhibit progression of structural joint damage in patients with RA of 
<5 years’ duration (Nishimoto et al., 2007). A total 306 Japanese patients were randomly 
assigned to two groups: (i) TCZ 8 mg/kg (n = 158) and (ii) conventional disease-modifying 
anti-rheumatic drug (DMARD) therapy (n = 148). At week 52, the TCZ group showed 
statistically less radiographic change in modified Total Sharp Score (mTSS) (mean 2.3) than 
the DMARD group (mean 6.1). The TCZ group also showed significantly better results than 
the DMARD group in ACR20, 50, and 70 responses, DAS28ESR, and Modified Health 
Assessment Questionnaire (MHAQ) scores. 
 
 
Population
Size (n=) Subject 
Control 
arm Primary endpoint 
Dura- 
tion 
SAMURAI 
(Nishimoto 
et al., 2007) 
refractory to 
DMARDs 
n=306
TCZ DMARDs 
ACR, DAS28ESR, 
mHAQ, and mTSS 
at week 52
52 w 
SATORI 
(Nishimoto 
et al., 2009b) 
refractory to 
MTX 
n=125
TCZ+ 
placebo 
MTX+ 
placebo ACR at week 24 24 w 
RADIATE 
(Emery et 
al., 2008) 
refractory to 
anti-TNFs 
n=498
MTX+ 
TCZ 
MTX+ 
placebo ACR at week 24 24 w 
OPTION 
(Smolen et 
al., 2008) 
refractory to 
MTX 
n=623
MTX+ 
TCZ 
MTX+ 
placebo ACR at week 24 24 w 
TOWARD 
(Genovese 
et al., 2008) 
refractory to 
DMARDs 
n=1220
DMARDs+ 
TCZ 
DMARDs+ 
placebo ACR at week 24 24 w 
AMBITION 
(Jones et al., 
2010) 
MTX-naïve or 
MTX-free for ≥6 
months 
n=673
TCZ MTX ACR at week 24 24 w 
LITHE 
(Kremer et 
al., 2011) 
refractory to 
MTX 
n=1196
MTX+ 
TCZ 
MTX+ 
placebo 
ACR at week 24; 
mTSS and HAQ at 
week 52
2 y 
Table 1. Phase III trials of TCZ in patients with RA 
SATORI (Study of Active controlled Tocilizumab mOnotherapy for Rheumatoid arthritis 
patients with an Inadequate response to metotrexate) was a 24-week, multicenter, 
randomized, double-blind, placebo-controlled phase III trial in patients with RA in whom 
the response to MTX was inadequate (Nishimoto et al., 2009b). A total 125 Japanese patients 
were randomly assigned to one of two groups: (i) TCZ 8 mg/kg plus MTX placebo (n = 61) 
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and (ii) TCZ placebo plus MTX (n = 66). At week 24, 25.0% in the MTX group and 80.3% in 
the TCZ group achieved ACR20 response. Additionally, serum vascular endothelial growth 
factor (VEGF) levels were significantly decreased by TCZ treatment, but not by MTX 
treatment. 
RADIATE (Research on Actemra Determining effIcacy after Anti-TNF failurEs) was a 24-
week, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III 
trial to evaluate the efficacy and safety of TCZ in patients with active RA refractory to TNF 
antagonist therapy (Emery et al., 2008). A total 498 US and Western Europe patients were 
randomly assigned to three groups: (i) TCZ 8 mg/kg plus MTX (n = 175), (ii) TCZ 4 mg/kg 
(n = 163) plus MTX, and (iii) TCZ placebo plus MTX (n = 160). ACR20 was achieved at 24 
weeks by 50.0%, 30.4% and 10.1% of patients in the 8 mg/kg, 4 mg/kg and control groups, 
respectively. Patients responded regardless of most recently failed anti-TNF or the number 
of failed treatments. 
OPTION (tOcilizumab Pivotal Trial in methotrexate Inadequate respONders) was a 24-
week, multicenter, randomized, double-blind, placebo-controlled phase III trial in patients 
with active RA in whom the response to MTX was inadequate (Smolen et al., 2008). A total 
623 patients from 17 countries were randomly assigned to three groups: (i) TCZ 8 mg/kg 
plus MTX (n = 205), (ii) TCZ 4 mg/kg (n = 214) plus MTX, and (iii) placebo plus MTX (n = 
204). ACR20 achieved at 24 weeks by 59%, 48%, and 26% of patients in the 8 mg/kg, 4 
mg/kg and control groups, respectively. Significantly greater numbers of patients receiving 
TCZ showed ACR50/ACR70 responses or clinical remission (DAS28ESR <2.6) at week 24 
than did those receiving placebo. In patients receiving TCZ, there were greater 
improvements in HAQ-DI score, the Short-Form 36 Health Survey (SF-36), and Functional 
Assessment of Chronic Illness Therapy (FACIT)-Fatigue assessment indicating that TCZ 
treatment significantly improves physical and mental function. 
TOWARD (Tocilizumab in cOmbination With traditional DMARD therapy) was a 24-week, 
multicenter, randomized, double-blind, placebo-controlled phase III trial to evaluate the 
efficacy and safety of TCZ combined with conventional DMARDs in patients with active RA 
(Genovese et al., 2008). A total 1220 patients from 18 countries were randomly assigned to 
two groups: (i) TCZ 8 mg/kg plus DMARD (n = 805) and (ii) TCZ placebo plus DMARD 
therapy (n = 415). ACR20 achieved at 24 weeks 61% for TCZ 8 mg/kg versus 25% for 
placebo. Similar to the results of OPTION, the TCZ group showed significantly better results 
than the placebo group in ACR50/ACR70 response, clinical remission rate (DAS28ESR 
<2.6), HAQ-DI, SF-36 and FACIT-Fatigue assessment. 
AMBITION (Actemra versus Methotrexate double-Blind Investigative Trial In mONotherapy) 
was a 24-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled 
phase III trial evaluating the efficacy and safety of TCZ monotherapy versus MTX in patients 
with active RA (Jones et al., 2010). A total of 673 patients from the US, Canada, and Israel were 
randomly assigned to three groups: (i) MTX (escalating dose regimen: initial dose 7.5 
mg/week, increasing to 15 mg/week at week 4 and 20 mg/week at week 8) for 24 weeks (n = 
284), (ii) TCZ 8 mg/kg for 24 weeks (n = 288), and (iii) TCZ placebo for 8 weeks then TCZ 8 
mg/kg for 16 weeks (n = 101). The intention-to-treat analysis demonstrated that TCZ was 
better than MTX treatment with a higher ACR20 response (69.9 vs 52.5%; p<0.001) and rate of 
DAS28ESR <2.6 (33.6 vs 12.1%) at week 24. The superiority of TCZ to MTX was observed in 
the intention-to-treat population from week 2 and throughout this study. The proportion of 
ACR50 (44%) and ACR70 (28%) responders at week 24 was also statistically superior for TCZ 
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compared with MTX (weighted difference between treatments: 0.12 for ACR50 (95% 
confidence interval (CI) 0.04 to 0.20; p = 0.002); and 0.14 for ACR70 (95% CI 0.07 to 0.22; 
p<0.001). The superiority of TCZ to MTX was also shown in improvement of HAQ-DI at week 
24. No significant difference was seen in the incidence of serious adverse events between TCZ 
treatment (3.8%) and MTX treatment (2.8%) (p = 0.50). 
LITHE (tociLIzumab safety and THE prevention of structural joint damage) is a 2 (or 3)-
year, multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating 
the ability of TCZ add-on therapy to inhibit progression of structural joint damage and 
improve physical function in patients with moderate to severe RA who respond 
inadequately to MTX. A total of 1196 patients from 14 countries were randomly assigned to 
three groups: (i) placebo plus MTX (n = 393), (ii) TCZ 4 mg/kg plus MTX (n = 399), and (iii) 
TCZ 8 mg/kg plus MTX (n = 398). Results from year 1 were reported (Kremer et al., 2011). 
Mean change in the total Genant-modified Sharp score was 0.29 and 0.34 with TCZ 8 mg/kg 
plus MTX and 4 mg/kg plus MTX, respectively, versus 1.13 with placebo plus MTX (P 
<0.0001). Additionally, the HAQ-DI significantly decreased in the groups of TCZ (8 mg/kg 
and 4 mg/kg) add-on treatment compared with the group with placebo plus MTX. 
3.2 Additional remarks 
MTX has the highest efficacy among conventional DMARDs and has been used as an anchor 
drug in the treatment of RA. The AMBITION study and the SATORI study demonstrated 
that TCZ monotherapy is superior to MTX monotherapy. Several studies have demonstrated 
that MTX monotherapy is equivalent or superior to TNF inhibitor monotherapy (Donahue 
et al., 2008). Comparison of TCZ with abatacept demonstrated that the rate of withdrawal 
due to no effect in TCZ treatment was lower than that in abatacept treatment (Leffers et al., 
2011). A meta-analysis revealed that the effectiveness of TCZ appeared to be greater for 
ACR70 (Bergman et al., 2010). Thus, TCZ is superior to MTX, TNF inhibitors, and abatacept 
in the case of monotherapy. The superiority between TCZ monotherapy and TCZ plus MTX 
treatment has not yet been established. Yamanaka et al. (2011) reported that the 
improvement of DAS28ESR and HAQ-DI in TCZ plus MTX treatment was better than that 
in TCZ monotherapy. Nakashima et al. (2010) reported that there was no significant 
difference in the improvement of DAS28ESR between TCZ monotherapy and TCZ plus 
MTX treatment. Data from the ACT-RAY study demonstrated that TCZ provided clinical 
benefit, regardless of whether it was given in combination with MTX or as a monotherapy 
(Dougados et al., 2011). 
4. Safety and tolerability 
Infections are the most frequent adverse events during therapy with TCZ and other 
biologics or DMARDs. In the AMBITION study, TCZ monotherapy was compared with 
MTX monotherapy (Jones et al., 2010). Infection rates per patient year were similar (TCZ 
1.06 vs MTX 1.09). In both groups, nasopharyngitis and upper respiratory tract infection 
were common. The common serious infections were pneumonia. Neither opportunistic 
infections nor tuberculosis were reported in the patients receiving TCZ. Similar results were 
observed in a meta-analysis of TCZ monotherapy in Japanese patients (Nishimoto et al., 
2010). Long-term exposure did not increase the incidence of serious infections. TCZ may not 
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increase the risk of de novo infection of tuberculosis. TCZ did not affect the humoral 
response to influenza vaccination (Tsuru et al., 2008). 
Infusion reactions (any adverse event occurring during, or within 24 h after infusion) 
occurred in 5.6% of patients with TCZ (Jones et al., 2010). The majority occurred during the 
first two infusions, and no serious infusion reactions were reported. In the meta-analysis of 
TCZ monotherapy, total 133 infusion reactions were observed in 93 patients (Nishimoto et 
al., 2010). Most of them occurred within the first four infusions. Headache, increased blood 
pressure, and pruritus were common. Anaphylactic reactions were observed in 3 patients. 
In worldwide Roche clinical trials, the rate of malignancies in patients receiving TCZ was 
11.6 events per 1000 patient-years while the rate in the patients receiving synthetic DMARDs 
was 17.7 events per 1000 patient-years (van Vollenhoven et al., 2010). As it usually takes 
several years before a malignant neoplasm grows to be clinically recognized after the 
appearance of the first malignant cell, TCZ may not have been involved in the 
carcinogenesis of the malignancies found during TCZ treatment to date. 
Decreases in the neutrophil count were commonly observed in patients receiving TCZ. In 
the meta-analysis of TCZ monotherapy, grade 2 (<1500–1000/µL) and grade 3 neutropenia 
(<1000–500/µL) were observed in 92 (15.3%) and 36 patients (6.0%), respectively (Nishimoto 
et al., 2010). However, the decreases were not progressive, and neither febrile neutropenia 
nor agranulocytosis occurred. There was no obvious association between decreases in 
neutrophils and the occurrence infections. Decreases in the neutrophil are probably due to 
inhibition of the biological effects of IL-6 on recruitment of neutrophils into peripheral 
blood, not due to myelosuppression. Transient or intermittent elevations of alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) have often been observed in 
patients receiving TCZ. The incidence of elevations of AST or ALT in patients treated with 
TCZ monotherapy was no more than that in patients treated with MTX monotherapy (Jones 
et al., 2010). Prolonged exposure to TCZ therapy did not appear to be associated with an 
increased likelihood of developing increases in ALT or AST because the numbers of patients 
developing increased ALT or AST values was highest in the first 6 months of treatment 
(Australian Government, 2011). Mean total cholesterol (T-cho) rose upon treatment with 
TCZ, but showed no continuous increase. As high-density lipoprotein (HDL) also increased, 
the atherogenic index [(T-cho – HDL)/HDL] did not change. Small low-density lipoprotein 
(LDL), which may be proatherogenic, did not increase with TCZ treatment while both large 
very low density lipoprotein (VLDL) and small HDL increases were observed (McInnes et 
al., 2010). Inhibition IL-6 signaling decreases lipoprotein A serum levels which correlate 
with coronary heart disease (Schultz et al., 2010; Daneshet al., 2000). Treatment with TCZ 
may not increase the risk of cardiovascular disease. 
Gastrointestinal (GI) perforation occurred in 26 cases out of 4009 patients treated with TCZ 
in worldwide Roche clinical trials (van Vollenhoven et al., 2009). The rate of GI perforations 
was 2.8 events per 1000 patient-years with TCZ therapy while the rate in patients with RA 
who were exposed to corticosteroids was 3.9 events per 1000 patient-years. The majority of 
the patients who experienced GI perforations treated with TCZ were also receiving 
corticosteroids, NSAIDS, and MTX. GI perforations occur mainly in lower GI tract, and 16 of 
the 18 patients with colonic perforations had diverticulitis. Prevention of constipation is 
important not only to reduce the incidence of colonic perforations but also to improve 
quality of life. A case of multiple ulcers in the small and large intestines during TCZ therapy 
has been reported (Iwasa et al., 2011). In mice, Il-6 signal is necessary for the development of 
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lamina propria TH17 cells which may play a role in the maintenance of intestinal mucosal 
homeostasis (Atarashi et al., 2008). A causal relationship between TCZ and gastrointestinal 
perforation/ulceration should be addressed in future studies. 
Experience with TCZ use in human pregnancy is very limited. Thirty-three pregnancies 
were reported in 32 patients (19 to 42 years) (Rubbert-Roth et al., 2010). Of the 32 patients, 26 
received TCZ + MTX and 6 received TCZ monotherapy or TCZ + DMARD other than MTX. 
In patients who continued their pregnancies, TCZ and MTX were discontinued when the 
pregnancy was discovered. Of 11 term deliveries (2 received TCZ monotherapy, 9 received 
TCZ + MTX), 10 were of healthy newborns. One infant died of ARDS 3 days after 
emergency cesarean section. It is difficult to evaluate the safety of TCZ during pregnancy 
from the current data. 
In conclusion, clinical trials demonstrated that TCZ was generally well tolerated in patients 
with active RA. The incidence of adverse events of TCZ monotherapy is no more than that 
of MTX monotherapy. Also, the risk of adverse events is comparable with that of other 
biologics and the risk of serious infection may be less than that for TNF inhibitors (Campbell 
et al, 2011). There was no increase in the frequency of adverse events with long-term 
treatment with TCZ (Nishimoto et al., 2010). 
5. The advantages, and potential advantages, of TCZ 
5.1 Synovitis 
The characteristic pathophysiology of RA is the destruction of bone and cartilage due to 
“persistent” synovitis; however, the mechanism of this “persistence” is not yet clear. It is 
reported that an IL-17A-triggered positive-feedback loop of IL-6 expression is present in 
fibroblasts (Ogura et al., 2008). Moreover, IL-6 stimulates megakaryocytes to increase 
platelet counts and induces platelet activation (Oleksowicz et al., 1994; Kaser et al., 2009), 
while platelet-derived microparticles in turn prominently elicit IL-6, not TNF, from synovial 
fibroblasts (Boilard et al., 2010). These phenomena may be involved in “persistent” 
inflammation. TCZ is the only drug that can directly cut these positive-feedback loops. 
5.2 Insulin resistance 
IL-6 is involved in the pathology of type II diabetes mellitus related insulin resistance (Fève 
& Bastard, 2009). The expression of IL-6 was markedly increased (up to 15-fold) in human 
fat cells from insulin-resistant individuals (Rotter et al., 2003). Inhibition of IL-6 signaling 
affects insulin resistance in a positive way (Schultz et al, 2010). A significant decrease of 
HbA1c was observed at only 1 month after TCZ treatment (Ogata et al., 2011a). Thus, TCZ 
may help to resolve insulin RA patients.  
5.3 Malignancies 
TCZ was originally planned as an anti-myeloma drug because TCZ suppressed growth of 
the IL-6-dependent myeloma cell line, KPMM2 (Mihara et al., 2005). In fact, in an RA patient 
with IgA-kappa type multiple myeloma, TCZ not only improved RA symptoms 
dramatically but also stabilized serum IgA levels for 13 months (Matsuyama et al,. 2011). 
TCZ decreases the serum levels of VEGF (Nishimoto et al., 2009b). This effect may interfere 
with the angiogenesis and growth of tumors. For example, the antitumor effect of TCZ for 
oral squamous cell carcinoma has been reported (Shinriki et al., 2009). Targeting of the IL-6 
system may be beneficial in the treatment of malignancies (Hong et al., 2007).  
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5.4 Mycobacterium infection 
The TNFǂ -/- mice or the IL-6 -/- mice demonstrated that TNF is critical for initiation of the 
granulomatous response, and IL-6 plays a key role in the granuloma maintenance response 
(Welsh et al., 2008). Unlike Il-6 -/- mice, TCZ does not completely inactivate the IL-6 system 
because TCZ works as a competitive inhibitor of IL-6. Moreover, TCZ, unlike TNF 
inhibitors, does not inhibit M. tuberculosis antigen-induced interferon gamma (IFN-Ǆ) 
production (Ogata et al., 2010b). TNF inhibitors increase the risk of infection or reactivation 
of M. tuberculosis while TCZ does not in clinical practice. Of course, TCZ should not be used 
in the patients with active mycobacterium infection. However, TCZ may be a candidate for 
intractable RA patients with mycobacterium infection which is treated. A patient with 
intractable RA was treated with TCZ without aggravation of M. avium infection which had 
been treated in advance (Nakahara et al., 2010). 
5.5 Anemia 
IL-6 increases the production of hepcidin, which is an iron-regulatory peptide secreted from 
liver cells, inhibits the signal transduction of erythropoietin, and causes anemia (Ganz and 
Nemeth 2009). Therefore, inhibition of IL-6 signaling by TCZ significantly improves anemia 
caused by chronic inflammation and benefits patients'general physical condition (Song et al., 
2010).  
5.6 Amyloidosis 
Secondary amyloidosis is a life-threatening complication of RA. Mortality, amyloid burden, 
and renal prognosis significantly correlate with serum amyloid A (SAA) concentration. As 
amyloid deposits regressed in 60% of patients who had a median SAA concentration of less 
than 10 µg/ml, normalization of the SAA concentration not only prevents but also treats 
secondary amyloidosis (Lachmann et al., 2007). TCZ treatment almost completely 
normalizes the serum SAA level because IL-6 signal is essential for the expression of SAA 
(Hagihara et al., 2005). Therefore, TCZ is very useful for the treatment of secondary 
amyloidosis (Sato et al., 2009; Inoue et al., 2010).  
5.7 Osteoporosis 
IL-6 levels are significantly higher (30 to 1000-fold) in synovial fluid than in sera 
(Desgeorges et al., 1997), and IL-6 drives osteoclastgenesis (Le Goff et al., 2010). Since 
osteoclasts are primarily involved in bone resorption, reduction in their number would be 
anticipated to reduce bone loss. This expectation is supported by the results of Axmann et al 
(2009) who demonstrated that blockade of IL-6R dose dependently decreased the joint 
osteoclast count and the number of bone erosions. They concluded that the mechanism for 
this effect was that blockade of IL-6R negatively affects osteoclast differentiation (Axmann et 
al., 2009). 
6. Improving clinical outcomes 
6.1 Strategies for improving clinical outcomes 
The response rate and the speed of improvement basically depend on the ratio between the 
target cytokine and the biological agent which traps the target cytokine. To lessen the 
amount of the target cytokine, it is very important that any comorbidity (e.g., infectious 
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diseases, lifestyle diseases, etc.) is treated or controlled as well as possible before and during 
administration of biological agents. This not only stops stimulation of the production of 
inflammatory cytokines from factors other than RA, but also serves to reduce adverse 
events, which results in better efficacy and safety. This also directly improves physical 
function irrespective of disease activity (Radner et al., 2010). 
The standard dosage of TCZ for the treatment of RA is 8 mg/kg every 4 weeks. The serum 
TCZ concentrations 4 weeks after 3 doses are greater than 1 mg/mL, which is an effective 
dose, in about 80% of patients. However, this means that the serum TCZ concentrations are 
not sufficiently high in approximately 20% of patients. In these patients, increasing the 
dosage of TCZ and/or shortening the dosage interval may improve efficacy. Indeed, during 
clinical trials, it was observed that arthritis improved following the first dose but returned 
after 3 weeks in several patients. This suggested that the blood level could not be 
maintained over the 4-week period. I thus decided to give the second dose after an interval 
of 3 weeks following the first. By doing this, none of the patients suffered repeat 
deterioration by the time of the second dose in symptoms that had improved following the 
first, and no additive adverse effects were observed. A shorter dose interval at the start may 
be thought to be perfectly reasonable in terms of maintaining blood levels of biologics. In 
practice, this administration method is used for infliximab and abatacept. 
6.2 Clinical efficacy and safety in our experience 
6.2.1 Patients 
The subjects of this analysis were patients who met the 1987 revised criteria for the 
classification of RA from ACR. Patients were included in the analysis if they started 
treatment with TCZ for the first time after 16 April 2008 (the date of insurance approval in 
Japan) (Table 2). This is an extension of a previous study (Hirabayashi et al, 2010). Data were 
collected until 20 March 2010. More than 23 and 51 weeks had elapsed since the first 
administration of TCZ in all 101 and in 70 patients, respectively. To reduce adverse events, 
any comorbidity was treated or controlled as well as possible before giving TCZ. All 
patients had a thoracic CT scan and were tested for the tuberculin reaction (or 
QuantiFERON ®), anti-streptolysin O (ASO), anti-streptokinase (ASK), treponema pallidum 
haemagglutination (TPHA), hepatitis B surface antigen (and anti-hepatitis B core antigen 
antibody), anti-hepatitis C virus antibody, and -D-glucan in order to screen for infections. 
If tooth plaque or caries were present, I arranged for assessment and treatment by a dentist. 
If chronic rhinorrhea or nasal blockage was seen, the patient was assessed and treated by an 
otolaryngologist. Patients were asked whether they had hemorrhoids. Patients were 
required to abstain from smoking. 
Among the various therapies being used by the patients in the three months before they 
received TCZ, infliximab was discontinued at least one month before, adalimumab at least 
one week before, and etanercept at least 4 days before the new treatment commenced. 
Salazosulfapyridine, bucillamine, sodium aurothiomalate and mizoribine were discontinued 
upon initiating TCZ. The patients continued on MTX, tacrolimus and steroids at the same 
dose levels as before at least until dose 3 of TCZ. Then, MTX and tacrolimus were tapered 
off until 6 months after. The steroid dose was decreased slowly to avoid steroid withdrawal 
syndrome. There were no users of auranofin, D-penicillamine, hydroxychloroquine, 
minocycline or lobenzarit disodium. 
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Patient Characteristics  
Age, mean ± SD, median (min - max), years  60.6 ± 12.7, 61 (23 – 82) 
Male : Female  20 : 81 
Duration of disease, mean, years 11.3 
Steinbrocker Class (I, II, III, IV) : Stage (I, II, III, IV) 37, 49, 15, 0 : 16, 19, 15, 53 
DAS28ESR, mean ± SE 4.60 ± 0.12 
Previous medications No. of patients treated 
 Prednisolone 71  (mean dosage: 3.9 mg/day) 
 TNF inhibitors (IFX, ETA, ADA) 11 (8, 2, 1) 
 MTX 38 
 Tacrolimus  11 
 Other DMARDs 48 
 No DMARDs for 3 months prior to TCZ treatment 20 
Table 2. Patient demographics, clinical characteristics, and previous medications at baseline. 
SD: standard deviation. SE: standard error. ‘Previous medications’ denotes drugs used in 
the 3 months before administration of TCZ. IFX: Infliximab, ETA: etanercept, ADA: 
adalimumab. ‘Other DMARDS’ were sodium aurothiomalate, bucillamine, 
salazosulfapyridine, and mizoribine. 
6.2.2 Clinical efficacy 
The mean DAS28ESR at the start of TCZ treatment in all 101 patients was 4.60 ± 0.12 (mean 
± standard error of the mean (SEM)). Mean DAS28ESR had fallen below the remission 
threshold (<2.6) to 2.20 ± 0.10 after two doses and had further improved to 1.61 ± 0.08 at 23 
weeks (intention-to-treat with last observation carried forward (ITT-LOCF)) and 1.50 ± 0.09 
at 51 weeks (ITT-LOCF). The clinical response was evaluated using the European League 
Against Rheumatism (EULAR) response criteria. At 51 weeks (ITT-LOCF), 64 out of 70 
patients (91.4%) had achieved remission with treatment response of good in 91.4%, 
moderate in 7.1% and one case of no response. The no response seen beyond five doses was 
due to a rise in DAS28ESR associated with a temporary deterioration in symptoms due to 
factors other than RA and did not represent secondary non-response. To date, no patient has 
discontinued the treatment due to lack of response. 
Next, the patients were classified based on DAS28ESR into a high-activity group at >5.1, a 
moderate-activity group at 3.2-5.1 and a low-activity group at <3.2. Although mean 
DAS28ESR had been 5.84 ± 0.13 (n=36) in the high-activity group before treatment with 
TCZ, this improved rapidly to below the remission threshold to 2.31 ± 0.20 after 3 doses 
(after 11-12 weeks; Fig. 1a). Mean DAS28ESR further improved to 1.92 ± 0.15 at 23 weeks 
and 1.66 ± 0.17 at 51 weeks. TCZ proved to be very effective regardless of baseline disease 
activity. Also, patients were classified based on disease duration into three groups (≥10 
years, 2≤~<10, <2). Although mean DAS28ESR had been 4.57 ± 0.21 (n=30) in the ≥10 years 
group before treatment, this improved rapidly to below the remission threshold to 2.30 ± 
0.17 after 2 doses (after 7 weeks; Fig. 1b). Mean DAS28ESR further improved to 1.60 ± 0.14 at 
51 weeks. TCZ proved to be effective regardless of disease duration. However, in the ≥10 
years group, the number of swelling joints rapidly decreased while the number of joints 
with tenderness decreased slowly, indicating that inflammation had subsided rapidly but 
that tenderness at the damaged joints was prolonged. 
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             a                                           b 
Fig. 1. Change in DAS28ESR by disease activity at baseline (a) and by duration of disease 
(b). Mean values shown. The criteria for exclusion from the analysis set were as follows: (i) 
autoimmune disease comorbidities except Sjögren’s syndrome and Hashimoto’s disease, (ii) 
functional class IV based on the Steinbrocker criteria, (iii) presence of active infection, (iv) 
pregnancy, (v) drug poisoning, including alcohol, (vi) lymphocyte count £ 500 cells/mL, 
and (vii) positive serum ǃ-D-glucan. The method of administering TCZ that has received 
insurance approval in Japan is continuous infusion of a dose of 8 mg/kg over a period of at 
least 1 hour once every 4 weeks. The interval between infusions was shortened to 3 weeks 
between the first and second infusions only, and an interval of 4 ± 1 weeks was used 
thereafter. Treatment was continued unless there were adverse events requiring 
discontinuation or the patient requested that treatment be stopped. 
6.2.3 Safety 
A total of 72 adverse events occurred in 64 of the 101 patients and these are listed in Table 3. 
The adverse events seen during infusion were transient bone pain (back pain, lumbar 
discomfort and ischial pain). These all appeared a few minutes into infusion and 
disappeared within a few minutes. Infections were the most frequent adverse events. 
Nasopharyngitis (common cold) was most frequent among the infections; however, the 
frequency was similar to that in normal individuals. A total of 10 serious adverse events 
requiring hospitalization occurred in 8 patients. Three patients developed pneumonia. A 60-
year-old woman with old tuberculosis and bronchiectasis as comorbidities showed a slight 
rise over her previous level of hemosputum, and bacterial pneumonia appeared 
subsequently. An 80-year-old woman was suspected of having pneumonia due to Chlamydia 
pneumoniae. Both recovered with treatment. A 67-year-old man developed pneumocystis 
carinii pneumonia followed by cytomegalovirus pneumonia and died. MTX was 
administrated concurrently to only this person due to scleritis suggesting vasculitis. A 68-
year-old man had chronic pancreatitis as a comorbidity with several episodes of acute 
exacerbations before exposure to TCZ. He died of an acute exacerbation of chronic 
pancreatitis. One patient who died due to cerebellar infarction was elderly, at 82 years of 
age, and had once suffered strokes in the past. A patient with malignant lymphoma 
discovered as a left axillary mass underwent PET-CT scan to assess the activity of interstitial 
pneumonia before being treated with TCZ. Accumulation was picked up in the left axillary 
lymph nodes. Tiny lymphadenopathy was found at the same site by CT scan. 
Retrospectively, it may be inferred that the accumulation seen by PET had been the early 
stages of malignant lymphoma. A patient who had developed colitis probably due to viral 
infection recovered quickly. 
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PT (MedDRA Ver13.0) a b
Adverse drug reactions
Bone pain 2 5
  Total 2 5
Events possibly related to TCZ
Nasopharyngitis 13 15
Sinusitis 4 4
Pneumonia* 1 2
Cystitis 3 3
Periodontitis 2 2
Otitis media 3 3
Paronychia 1 1
Infection 1 1
Bronchitis 1 2
Pneumocystis jiroveci
Pneumonia*
1 1
Gastroenteritis 1 1
Pneumonia chlamydial* 1 1
Herpes zoster 1 1
  Total 33 37
a b
Events hardly related to TCZ
Rhinitis allergic 2 2
Diarrhoea 3 3
Haemorrhoids 2 2
Rash 2 2
Conjunctivitis allergic 1 1
Abdominal pain upper 1 1
Platelet count decreased 1 1
Asthma 1 1
Ileus 1 1
Pancreatitis acute* 1 2
Cough 1 1
Colitis* 1 1
Dizziness 1 1
  Total 18 19
Events unrelated to TCZ
Liver disorder 3 3
WBC count decreased 1 1
Lymphoma* 1 1
Cerebral infarction* 2 2
Hypoglossal nerve disorder 1 1
Toxic skin eruption 1 1
Bowen’s disease 1 1
Compression fracture 1 1
  Total 11 11
Table 3. Adverse events. *serious adverse events requiring hospitalization, a: No. of patients, 
b: No. of events. WBC: white blood cell. 
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Fig. 2. Change in laboratory findings. a: CRP, b: ESR. c: MMP-3, d: WBC, e: PLT, f: Hb, g: 
AST and ALT, h: T-cho, HDL, and LDL. Mean values shown. Bars indicate SE. 
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Changes in laboratory findings are shown in figure 2. CRP virtually normalized in all 
patients after the first dose of TCZ (1.61 ± 0.16 → 0.20 ± 0.03 mg/dL) (Fig. 2a). Erythrocyte 
sedimentation rate (ESR) likewise normalized quickly after the first dose (37.9 ± 2.47 → 8.8 ± 
0.85 mm/h) (Fig. 2b). Both followed a normal course afterwards as well. The level of matrix 
metalloproteinase-3 (MMP-3) gradually decreased from 207.7 ng/ml at baseline to 88.4 ± 
8.79 ng/ml at 51 weeks (Fig. 2c). The mean leukocyte count was 8260 ± 278 /mL at baseline; 
however, this decreased to approximately 5500 /mL after the first dose. There was no 
progressive fall as seen in myelosuppression and no significant increase in infections (Fig. 
2d). Likewise, the mean platelet count of 328000 ± 9100 /mL at baseline decreased to 
approximately 220000 /mL after the first dose (Fig.2e). The hemoglobin (Hb) level rose 
gradually and anemia improved after treatment with TCZ began (Fig. 2f). Figure 2g shows 
changes over time in AST and ALT as an index of liver function. Even though abnormal 
values for AST or ALT were seen, these were transient and all were of grade I based on the 
National Cancer Institute Common Toxicity Criteria. Mean total T-cho at baseline was 201.7 
± 3.46 mg/dL. Upon treatment with TCZ, it rose to approximately 220 mg/dL and then 
decreased to 210 mg/dL (Fig. 2h). I provided lifestyle guidance and monitored the clinical 
course without administering drug treatment at least until dose 3. Several patients whose 
level nevertheless exceeded 280 mg/dL were treated with a HMG-CoA reductase inhibitor. 
HDL and LDL at baseline were 58.4 ± 1.55 mg/dL and 123.5 ± 3.08 mg/dL, respectively. 
HDL rose to approximately 65 mg/dL. LDL transiently rose to approximately 130 mg/dL 
but returned to baseline thereafter (Fig. 2h). I encountered no laboratory test abnormalities 
so severe that treatment with TCZ could not continue. TCZ was generally well tolerated, as 
was observed in clinical trials. 
7. Impact of TCZ on the treatment strategy for rheumatoid arthritis 
Examination by MRI of RA patients has revealed that in approximately half of the patients, 
bone destruction in joints had begun within 4 months of the onset of inflammation 
(McQueen et al., 1998). It is, therefore, important to achieve remission within 4 months of 
the onset of RA to reduce the chances of bone destruction. In treatment with the 
conventional DMRADs including MTX and with TNF inhibitors, patients who do not 
respond or who show insufficient response are often encountered. In these patients, bone 
destruction often progresses whilst disease activity remains uncontrolled. Medically, there is 
no reason why MTX or TNF inhibitors must be used initially. Therefore, to achieve tight 
control, and to reduce the number of such unfortunate patients, TCZ monotherapy is 
recommended from the beginning in new onset patients because it shows high efficacy and 
response rates. After tight control is achieved, how long to continue TCZ treatment and 
what treatment to use after completion of TCZ treatment are topics for future study. 
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